What Is a GLP-1 Receptor Agonist?
GLP-1 stands for glucagon-like peptide-1, a hormone your gut naturally releases after eating. It signals the pancreas to release insulin, slows stomach emptying (so you feel full longer), and signals the brain to reduce appetite. GLP-1 receptor agonists are medications that mimic this hormone — and they've transformed how we treat both type 2 diabetes and obesity.
These medications do not cause hypoglycemia (low blood sugar) on their own because they only stimulate insulin release when blood sugar is actually elevated — a significant safety advantage over older diabetes drugs.
Semaglutide: Ozempic, Wegovy & Rybelsus
Semaglutide is currently the most widely prescribed GLP-1 agent in the United States. It comes in three formulations:
Ozempic (injectable semaglutide — FDA approved for type 2 diabetes)
Ozempic is a once-weekly subcutaneous injection approved for type 2 diabetes management. It lowers A1c significantly and also reduces the risk of major cardiovascular events (heart attack, stroke) in people with established heart disease. While patients often lose weight on Ozempic, it is not FDA approved for weight loss — Wegovy is.
Wegovy Pills (Oral Semaglutide) — FDA Approved for Chronic Weight Management
Wegovy Pills contain the same semaglutide molecule as Wegovy injection. FDA-approved for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related condition (such as type 2 diabetes, high blood pressure, or high cholesterol) as an adjunct to reduced-calorie diet and increased physical activity. It offers the option of oral semaglutide for chronic weight management for those who prefer pills over injections.
Wegovy (injectable semaglutide — FDA approved for chronic weight management)
Wegovy contains the same semaglutide molecule as Ozempic but at a higher maximum dose (2.4 mg vs 1.0 mg weekly). It's approved for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related condition. Clinical trials showed average weight loss of 15% of body weight — a landmark result that transformed obesity medicine.
Rybelsus (oral semaglutide — FDA approved for type 2 diabetes)
Rybelsus is the first oral GLP-1 medication — the same semaglutide molecule in pill form. It must be taken on an empty stomach with a small amount of water and no other food or drink for 30 minutes. It's approved for type 2 diabetes, not weight loss, though weight reduction is a common benefit.
Tirzepatide: Mounjaro & Zepbound
Tirzepatide is a newer and more powerful agent that activates two receptors — both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). This dual action produces more potent effects on blood sugar and weight than GLP-1 alone.
Mounjaro (tirzepatide — FDA approved for type 2 diabetes)
Mounjaro is a once-weekly injection for type 2 diabetes that produces some of the most impressive A1c reductions seen in clinical trials. Like Ozempic, weight loss is common but the diabetes indication is the approved use.
Zepbound (tirzepatide — FDA approved for chronic weight management)
Zepbound is Mounjaro rebranded for weight loss. Clinical trials showed average weight loss of 20–22% of body weight — the largest ever seen in a weight loss medication trial. It's approved for obesity or overweight with a weight-related health condition.
Older GLP-1 Agents
Several older GLP-1 medications are still in use, primarily for diabetes:
- Victoza (liraglutide): Once-daily injection for type 2 diabetes. Also has cardiovascular benefit data.
- Saxenda (liraglutide): The same molecule as Victoza at a higher dose, approved for weight loss.
- Trulicity (dulaglutide): Once-weekly injection for type 2 diabetes with heart and kidney protection data.
- Byetta / Bydureon (exenatide): Earlier GLP-1 agents, less commonly prescribed now with newer options available.
Side-by-Side Comparison
| Brand Name | Generic | Type | FDA Approval | How Often |
|---|---|---|---|---|
| Ozempic | Semaglutide | GLP-1 | Type 2 Diabetes | Once weekly (injection) |
| Wegovy | Semaglutide | GLP-1 | Weight Loss | Once weekly (injection) |
| Rybelsus | Semaglutide | GLP-1 | Type 2 Diabetes | Once daily (pill) |
| Mounjaro | Tirzepatide | GIP + GLP-1 | Type 2 Diabetes | Once weekly (injection) |
| Zepbound | Tirzepatide | GIP + GLP-1 | Weight Loss | Once weekly (injection) |
| Victoza | Liraglutide | GLP-1 | Type 2 Diabetes | Once daily (injection) |
| Saxenda | Liraglutide | GLP-1 | Weight Loss | Once daily (injection) |
| Trulicity | Dulaglutide | GLP-1 | Type 2 Diabetes | Once weekly (injection) |
Which Medication Is Right for You?
Choosing among these medications depends on several factors that your endocrinologist will evaluate:
- Primary goal: Is the main concern blood sugar control, weight loss, or both?
- Insurance coverage: Coverage varies significantly between brands — your doctor can help navigate prior authorizations.
- Cardiovascular history: Some agents have specific data in patients with heart disease or kidney disease.
- Pill vs. injection preference: Rybelsus is the only oral option.
- Side effect profile: Nausea, vomiting, and constipation are common, especially early on. Dose titration and dietary adjustments can minimize these.